Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis

28 August 2023 (09:06 - 09:24)

Organised by:

Video

Sign in for access options

Abstract

Slides

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on novel targets and treatments for heart diseases and diabetes

Professor J. Pernow (Stockholm, SE)

Presentation thumbnail

Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy

Doctor M. Elmegaard (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

GLP1 receptor agonists exhibit antioxidant and anti-inflammatory properties in human heart tissue via the canonical GLP1 receptor expression through a AMPK-mediated pathway

Doctor E. Cordeanu (Strasbourg, FR)

Abstract Slides Video

Presentation thumbnail

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

Doctor R. Mentz (Durham, US)

Abstract Slides Video

Access the full session

Session thumbnail

Novel targets and treatments for heart diseases and diabetes

The Event

Event poster

ESC Congress 2023

28 August 2023 09:06 CET

You may be interested in

Congress Presentation

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

Congress Session

Novel targets and treatments for heart diseases and diabetes

Congress Presentation

Evidence from international clinical trials in patients with chronic kidney disease (CKD) and type 2 diabetes

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources